Penfluridol: An Antipsychotic Agent Suppresses Metastatic Tumor Growth in Triple-Negative Breast Cancer by Inhibiting Integrin Signaling Axis.

These findings highlight a clinically approved antipsychotic drug with the potential to be repositioned immediately to treat metastatic triple-negative breast cancer in clinical trials.